Wednesday, June 10, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 37 of 1,261
  1. AR 132316

    TRATAMIENTO COMBINADO CON CLASCOTERONA Y MINOXIDIL

    CASSIOPEA S P A [IT] Β· Granted Jun 11, 2025 Β· Expires Jun 6, 2045

    granted
  2. US 12324843

    Compositions and methods for delivery of biomacromolecule agents

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Jun 10, 2025 Β· Expires Jun 5, 2045

    granted
  3. US 12324798

    Leonurine nanocomposite hydrogel and preparation methods and applications thereof

    WEST CHINA HOSPITAL, SICHUAN UNIVERSITY Β· Granted Jun 10, 2025 Β· Expires Jun 5, 2045

    granted
  4. US 12325699

    Antibacterial compounds

    BLACKSMITH MEDICINES, INC. Β· Granted Jun 10, 2025 Β· Expires Jun 5, 2045

    granted
  5. US 12324837

    ROR1-specific antigen binding molecules

    ALMAC DISCOVERY LIMITED Β· Granted Jun 10, 2025 Β· Expires Jun 5, 2045

    granted
  6. US 12325755

    Macropinocytosing human anti-CD46 antibodies and targeted cancer therapeutics

    The Regents of the University of California Β· Granted Jun 10, 2025 Β· Expires Jun 5, 2045

    granted
  7. US 12326492

    Systems and methods of detecting interstitial cystitis

    LIPELLA PHARMACEUTICALS, INC. Β· Granted Jun 10, 2025 Β· Expires Jun 5, 2045

    granted
  8. US 12325732

    Pro-insulin aspart structure and method for preparing insulin aspart

    AMPHASTAR NANJING PHARMACEUTICALS INC Β· Granted Jun 10, 2025 Β· Expires Jun 5, 2045

    granted
  9. US 12325753

    Method of using an anti-transferrin receptor antibody to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy

    Dyne Therapeutics, Inc. Β· Granted Jun 10, 2025 Β· Expires Jun 5, 2045

    granted
  10. US 12324812

    Glucopyranosyl derivatives and their uses

    SUNSHINE LAKE PHARMA CO., LTD. Β· Granted Jun 10, 2025 Β· Expires Jun 5, 2045

    granted
  11. US 12325708

    Adenosine 2 receptor antagonists

    Nektar Therapeutics Β· Granted Jun 10, 2025 Β· Expires Jun 5, 2045

    granted
  12. US 12325854

    Crispr-CPF1-related methods, compositions and components for cancer immunotherapy

    Editas Medicine, Inc. Β· Granted Jun 10, 2025 Β· Expires Jun 5, 2045

    granted
  13. US 12325733

    Binding domain

    AUTOLUS LIMITED Β· Granted Jun 10, 2025 Β· Expires Jun 5, 2045

    granted
  14. US 12325710

    Substituted 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles for treating brain disorders

    The Regents of the University of California Β· Granted Jun 10, 2025 Β· Expires Jun 5, 2045

    granted
  15. US 12325711

    3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-Ξ±]pyrazine as an ion channel modulator

    PRAXIS PRECISION MEDICINES, INC. Β· Granted Jun 10, 2025 Β· Expires Jun 5, 2045

    granted
  16. US 12325752

    Immunoglobulin proteins that bind to NPR1 agonists

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jun 10, 2025 Β· Expires Jun 5, 2045

    granted
  17. US 12324802

    Modulators of cystic fibrosis transmembrane conductance regulator

    Vertex Pharmaceuticals Incorporated Β· Granted Jun 10, 2025 Β· Expires Jun 5, 2045

    granted
  18. US 12325715

    Fluorous metal chelates compositions

    The Regents of the University of California Β· Granted Jun 10, 2025 Β· Expires Jun 5, 2045

    granted
  19. US 12325688

    Gingerenone A prodrugs as sensotherapeutics and methods of use

    The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Jun 10, 2025 Β· Expires Jun 5, 2045

    granted
  20. US 12325691

    Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain

    The Board of Regents of the University of Texas System Β· Granted Jun 10, 2025 Β· Expires Jun 5, 2045

    granted
  21. US 12325750

    Anti-Dectin-2 antibodies and methods of using

    Bolt Biotherapeutics, Inc. Β· Granted Jun 10, 2025 Β· Expires Jun 5, 2045

    granted
  22. US 12324828

    Conjugates of a factor VIII moiety having an oxime-containing linkage

    Nektar Therapeutics Β· Granted Jun 10, 2025 Β· Expires Jun 5, 2045

    granted
  23. US 12324787

    Kits for preparing and delivering purified corticotropin

    ANI Pharmaceuticals, Inc. Β· Granted Jun 10, 2025 Β· Expires Jun 5, 2045

    granted
  24. US 12325703

    Fused ring compound as FGFR and VEGFR dual inhibitor

    CGeneTech (Suzhou, China) CO., Ltd. Β· Granted Jun 10, 2025 Β· Expires Jun 5, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.